Physician profile
Andrew Atton
NPI 1235124538
$777.18
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $777.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $175.84 | 2019 | |
| Novartis Pharmaceuticals Corporation | $124.29 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $91.08 | 2019 | |
| Sun Pharmaceutical Industries INC. | $88.51 | 2019 | |
| Mayne Pharma Commercial LLC | $83.42 | 2019 | |
| Lilly USA, LLC | $73.99 | 2019 | |
| Almirall LLC | $46.30 | 2019 | |
| Abbvie INC. | $43.29 | 2019 | |
| Ucb, INC. | $35.71 | 2019 | |
| Galderma Laboratories, L.P. | $14.75 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Atton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.